Polo-like Kinases (PLKs) are a family of highly conserved serine/threonine protein kinases that are essential for a variety of biological functions, including cell division and mitosis checkpoint regulation. Five PLKs (PLK 1-5) play a variety of roles in DNA damage response, intra-S-phase and G2/M checkpoints, spindle formation, and centrosome dynamics in mammals.
PLKs are distinguished by their Polo-box domain, which mediates protein interactions. Depending on the biological context, they are also regulated by transcription, proteolysis, and phosphorylation. PLKs are now understood to function in differentiated cells and link cell division to developmental processes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4268 | Rigosertib (ON-01910) | 592542-59-1 | Rigosertib (formerly also known as ON-01910) is a novel, potent and non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. |
|
V1575 | Rigosertib sodium (ON-01910) | 1225497-78-8 | Rigosertib sodium (formerly known as ON-01910; ON01910; Estybon), the sodium salt ofRigosertib, is a novel, potent and non-ATP-competitive inhibitor of PLK1 with potential anticancer activity. |
|
V1579 | Ro3280 (Ro5203280) | 1062243-51-9 | RO3280 (also known as Ro-5203280; RO 3280; Ro5203280; RO-3280) is a novel, potent and highly selective inhibitor of Polo-like kinase 1 (PLK1) with potential anticancer activity. |
|
V1581 | SBE 13 HCl | 1052532-15-6 | SBE 13 HCl (SBE13; SBE-13), the hydrochloride salt of SBE13, is a novel, potent and selective Polo-like Kinase 1 (PLK1) inhibitor with potential antineoplastic activity. |
|
V4581 | TAK-960 | 1137868-52-0 | TAK-960 (TAK960) is a novel, investigational, orally bioavailable, and selective inhibitor of polo-like kinase 1 (PLK1) with anticancer activity. |
|
V4582 | TAK-960 dihydrochloride | 1137868-52-0 | TAK-960 DiHCl, the dihydrochloride salt of TAK960, is an orally bioavailable, potent, and selective PLK1 polo-like kinase 1 (PLK1) inhibitor with anIC50of 0.8 nM at 10 μM ATP. |
|
V35228 | TAK-960 hydrochloride | 1137868-96-2 | TAK-960 HCl is a potent, orally bioavailable, selective polo-like kinase 1 (PLK1) inhibitor (antagonist) with IC50 of 0.8 nM. |
|
V35229 | TAK-960 monohydrochloride | 2108449-45-0 | TAK-960 mono HCl is a potent, orally bioavailable, selective polo-like kinase 1 (PLK1) inhibitor (antagonist) with IC50 of 0.8 nM. |
|
V1574 | Volasertib (BI 6727) | 755038-65-4 | Volasertib (formerly also known as BI6727, BI-6727, BI 6727) is a novel and highly potent dihydropteridinone-based Plk1 (polo-like kinase 1) inhibitor with potential antineoplastic activity. |
|
V79151 | YLT-11 | YLT-11 is a specific and orally bioactive PLK4 inhibitor (antagonist) with Kds of >10000, 653, >10000 and 5.2 nM for PLK1, PLK2, PLK3 and PLK4 respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
